Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Internal Medicine | Ophthalmology | Journal

Back to Journal Articles

Posterior Chamber Lens Shows Years of Benefit in Myopia

Last Updated: July 15, 2009.

Implantable Collamer lenses appear safe, efficacious and stable for treating moderate to high myopia over four years of follow-up, according to research published in the July issue of the Archives of Ophthalmology.

WEDNESDAY, July 15 (HealthDay News) -- Implantable Collamer lenses appear safe, efficacious and stable for treating moderate to high myopia over four years of follow-up, according to research published in the July issue of the Archives of Ophthalmology.

Kazutaka Kamiya, M.D., of the University of Kitasato School of Medicine in Kanagawa, Japan, and colleagues analyzed data from 34 patients with implantable Collamer lens implantation in 56 eyes. Efficacy, safety, stability, and other factors were assessed before surgery and at various time points up to four years.

The researchers found that, at four years after surgery, the mean logMAR uncorrected visual acuity was −0.03, and logMAR best spectacle-corrected visual acuity was −0.21. Also at this point, 79 percent of eyes were within ±0.5 D of the targeted correction, and 93 percent were within ±1.0 D. Mean changes in manifest refraction from one month to four years were −0.24 D. The authors further note that no patients developed vision-threatening complications during follow-up.

"In summary, our long-term results indicate that implantable Collamer lens implantation is safe and effective and provides predictable and stable refractive results in the correction of moderate to high myopia throughout a four-year observation. In addition, no vision-threatening complications occurred throughout the follow-up period," the authors conclude. "More prolonged careful observation for longer than four years is necessary to assess late-onset complications of this surgical technique."

A co-author has been a consultant for STAAR Surgical Company, the maker of the lens studied in this article.

Abstract
Full Text


Previous: Smoking Linked to More Rapid Multiple Sclerosis Progression Next: Study Sheds Light on Crohn’s Disease Pathogenesis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: